Recent Analysts’ Ratings Updates for BioNTech (BNTX)

Several brokerages have updated their recommendations and price targets on shares of BioNTech (NASDAQ: BNTX) in the last few weeks:

• 3/13/2025 – BioNTech is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $145.00 price target on the stock.
• 3/11/2025 – BioNTech had its price target lowered by analysts at Morgan Stanley from $145.00 to $139.00. They now have an “overweight” rating on the stock.
• 3/11/2025 – BioNTech had its price target raised by analysts at BMO Capital Markets from $130.00 to $143.00. They now have an “outperform” rating on the stock.
• 3/11/2025 – BioNTech had its “buy” rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $171.44 price target on the stock.

BioNTech Stock Performance

Shares of BNTX stock traded down $0.11 on Thursday, reaching $95.79. The stock had a trading volume of 80,538 shares, compared to its average volume of 784,764. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $22.99 billion, a price-to-earnings ratio of -45.62 and a beta of 0.30. The firm’s 50-day moving average is $112.10 and its two-hundred day moving average is $113.72.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.70. The firm had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business’s revenue for the quarter was down 19.5% compared to the same quarter last year. During the same period last year, the business posted $1.90 earnings per share. On average, research analysts expect that BioNTech SE will post -3.88 EPS for the current fiscal year.

Hedge Funds Weigh In On BioNTech

Several institutional investors and hedge funds have recently added to or reduced their stakes in BNTX. Wealth Enhancement Advisory Services LLC bought a new stake in BioNTech in the fourth quarter valued at approximately $238,000. Probity Advisors Inc. boosted its stake in BioNTech by 8.5% during the 4th quarter. Probity Advisors Inc. now owns 1,970 shares of the company’s stock valued at $224,000 after purchasing an additional 154 shares during the last quarter. Jefferies Financial Group Inc. bought a new stake in BioNTech during the fourth quarter worth $570,000. GF Fund Management CO. LTD. purchased a new stake in shares of BioNTech in the fourth quarter valued at about $235,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of BioNTech by 19.9% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 221,080 shares of the company’s stock worth $25,192,000 after buying an additional 36,746 shares in the last quarter. Institutional investors own 15.52% of the company’s stock.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.